Predicting Malignant Mesothelioma by Analyzing Serum N-ERC/Mesothelin, C-ERC/Mesothelin, Hyaluronan, Osteopontin, and Syndecan-1 Levels

Arslan S., Mundt F., METİNTAŞ S., AK G., Dobra K., Hjerpe A., ...More

EURASIAN JOURNAL OF PULMONOLOGY, vol.19, no.3, pp.130-138, 2017 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 19 Issue: 3
  • Publication Date: 2017
  • Doi Number: 10.5152/ejp.2017.50023
  • Journal Name: EURASIAN JOURNAL OF PULMONOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.130-138
  • Keywords: Hyaluronan, megakaryocyte potentiating factor, mesothelin, mesothelioma, osteopontin, syndecan-1, MEGAKARYOCYTE POTENTIATING FACTOR, PLEURAL MESOTHELIOMA, SOLUBLE MESOTHELIN, TUMOR-MARKER, TRIMODALITY TREATMENT, FAMILY PROTEINS, LUNG-CANCER, DIAGNOSIS, ASBESTOS, BIOMARKERS
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

Objective: Tumor biomarkers are promising study areas for the early or differential diagnosis of malignant pleural mesothelioma (MPM). This study aimed to determine the effectiveness of analyzing serum N-ERC/mesothelin, C-ERC/mesothelin, hyaluronan, osteopontin, and syndecan-1 levels for distinguishing patients with MPM from those with metastatic malignant pleural diseases (MMPDs), benign pleural diseases (BPDs), and benign asbestos pleurisy (BAP).